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Genome-wide Linkage Screen
in Familial Parkinson Disease Identifies
Loci on Chromosomes 3 and 18
Xiaoyi Gao,1,3 Eden R. Martin,1 Yutao Liu,2 Gregory Mayhew,1,4 Jeffery M. Vance,1
and William K. Scott1,*
Parkinson disease (PD) is a complex, multifactorial neurodegenerative disease with substantial evidence for genetic risk factors. We con-
ducted a genome-wide linkage screen of 5824 single-nucleotide polymorphisms in 278 families of European, non-Hispanic descent to
localize regions that harbor susceptibility loci for PD. By using parametric and nonparametric linkage analyses and allowing for genetic
heterogeneity among families, we found two loci for PD. Signiﬁcant evidence for linkage was detected on chromosome 18q11
(maximum lod score [MLOD]¼ 4.1) and suggestive evidence for linkagewas obtained on chromosome 3q25 (MLOD¼ 2.5). These results
were strongest in families not previously screened for linkage, and simulation studies suggest that these ﬁndings are likely due to locus
heterogeneity rather than random statistical error. The ﬁnding of two loci (one highly statistically signiﬁcant) suggests that additional
PD susceptibility genes might be identiﬁed through targeted candidate gene studies in these regions.Parkinson disease (PD [MIM 168600]) is a neurodegenera-
tive disorder affecting more than one million people in
the United States.1 It is characterized by progressive deple-
tion of dopaminergic neurons within the substantia nigra,
which results in the clinical symptoms of tremor, rigidity,
and bradykinesia. Despite inconsistent results from studies
aiming to establish evidence for a genetic component to
the etiology of PD,2 many genes have been identiﬁed in
which mutations cause a Mendelian form of PD (PARK2
[MIM 602544], PINK1 [MIM 608309], DJ1 [MIM 602533],
LRRK2 [MIM 609007], SNCA [MIM 163890], UCHL1
[MIM 191342]).3 Additionally, studies of the more
common, late-onset formof PDhave identiﬁed associations
between variants in several genes (MAPT4 [MIM 157140],
GBA5 [MIM 606463], FGF206,7 [MIM 605558], mitochon-
drial haplogroups8 [MIM 556500], and MAOB9–12 [MIM
309860]) and risk of PD. More complex patterns of
interaction among risk factors, including gene-gene13,14
and gene-environment interactions,15,16 have been
established. Common to all studies is the observation that
clinical and genetic heterogeneity likely underlies these
effects.3
Many genome-wide screens for loci linked or associated
with PD have been performed to date.17–27 Most of the
linkage studies in PD to date are based on microsatellite
marker sets. However, the development of modern geno-
typing methods allows more efﬁcient genotyping and
increased information extraction via dense maps of
single-nucleotide polymorphisms (SNPs). In order to
further identify candidate regions that harbor the genes
for PD, we extended our initial linkage screen of microsa-
tellite markers in 174 families17 with a genome-widelinkage screen (GWLS) of 5824 SNPs in an expanded data
set of 320 families.
For this study, participants from families with multiple
individuals affected with PD were ascertained for genetic
studies by 13 clinical sites. Clinical evaluations were
conducted by neurologists or by clinical staff trained and
supervised by a neurologist. Affected individuals possessed
at least two of the cardinal signs of PD (resting tremor,
rigidity, bradykinesia); unaffected individuals had no
clinical signs of PD; and unclear individuals showed only
one cardinal sign and/or atypical clinical signs. DNA was
extracted from whole blood samples with the PUREGENE
DNA puriﬁcation kit by Gentra (Minneapolis, MN). All
participants provided written consent for participation in
the study and were enrolled under protocols approved by
the institutional review boards at each participating site.
We conducted a GWLS with the Illumina Linkage Panel
IVb (containing 6008 SNPs) in 1546 individuals from 320
families. A genotyping efﬁciency of 95% was required to
retain a SNP for analysis, and unreliable markers were
identiﬁed by including four duplicated quality control
(QC) samples per 96-well PCR plate; markers with mis-
matched QC samples were removed from analysis.17 After
removing 160 markers with low-efﬁciency or mismatched
QC samples, 16 Y markers, and 8 pseudoautosomal XY
markers, 5824 SNPs (average spacing 0.62 cM) were
analyzed. Hardy-Weinberg equilibrium was evaluated in
one affected and one unaffected individual per family via
the Genetic Data Analysis program, and two SNPs with
signiﬁcant deviation from HWE in both groups (indicative
of potential genotyping errors) were removed from the
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Table 1. Description of 278 Families Included in the Genome-wide Linkage Screen
Original Screen
Families (N ¼ 158)
New Families
(N ¼ 120)
Total Families
(N ¼ 278)
Individuals affected with PD sampled 353 254 607
Unaffected individuals sampled 369 240 609
Individuals with unclear diagnosis sampled 74 49 123
Mean age at onset (standard error) in sampled, affected
individuals
59.9 (12.7) 60.8 (13.0) 60.2 (12.8)
Number of sampled affected sibpairs 150 78 228
Number of sampled affected relative pairs 76 72 147
Mean number (range) of sampled affected individuals per family 2.3 (2-5) 2.2 (2-5) 2.3 (2-5)
Proportion of families with sampled affected relative pairs 22% 44% 31%
Number of families included by clinical site
Baylor College of Medicine 7 6 13
Charlotte Neurologic Center 7 2 9
Duke University Medical Center 7 44 51
Emory University 22 9 31
University of Pennsylvania 12 5 17
Marshfield Clinic 12 1 13
Ohio State University 25 7 32
Rush-Presbyterian-St. Luke’s Hospital 8 2 10
University of California, Los Angeles 2 3 5
University of Kansas 16 1 17
University of Minnesota 34 24 58
University of Western Australia 4 0 4
Vanderbilt University 2 16 18the location of each SNP by extrapolating from the phys-
ical map location (NCBI Build 35) and the deCODE linkage
map (in cM). Family relationships were checked with
RELPAIR software.28 Nine individuals were removed from
analysis because of inconsistencies with the established
pedigree structure, but no families were removed.
After eliminating 42 families carrying known causative
mutations in the SNCA, PARK2, or LRRK2 genes, the ﬁnal
overall data set included 278 families of European, non-
Hispanic descent with two or more sampled individuals
with PD. This ﬁnal data set included 158 families from
our original screen and 120 new families. These families
are described in more detail in Table 1. The total number
of individuals with DNA samples available in the ﬁnal
data set was 1339 (an average of 4.8 individuals per family).
There were 607 individuals with PD, 609 unaffected indi-
viduals, and 123 individuals with unclear status. The
mean age at onset in individuals with PD was 60.2 years.
The data set included 228 affected sibpairs and 147 other
affected relative pairs. There were no differences in the
158 original families or 120 new families by mean age at
onset or mean number of individuals with PD per family.
However, a greater proportion of the new families (44%)
contained affected relative pairs compared to the original
screen families (22%), and there were differences in the
numbers of families contributed by site.
Parametric and nonparametric linkage analyses were per-
formed on autosomal and X chromosomes, via MERLIN
and MINX (MERLIN in X) software.29 Parametric linkage500 The American Journal of Human Genetics 84, 499–504, April 10analyses can be powerful methods for detecting linkage
when the true mode of inheritance is unknown as long as
both a dominant and a recessive model are used and locus
heterogeneity across families is considered.30–34 Therefore,
we used both dominant and recessive ‘‘affecteds-only’’
models for our parametric linkage analyses with model
parameters consistent with our previous report.17
Affecteds-only models utilize genotypes from unaffected
and unclear individuals only to establish linkage phase—
only individuals considered affected contribute to the
LOD score. Disease allele frequencies were set at 0.001
and 0.20 for the dominant and recessive model, respec-
tively. Marker allele frequencies were estimated from all
founders. We generated two-point and multipoint para-
metric maximum LOD (MLOD) scores allowing for hetero-
geneity. Moreover, we also calculated both two-point and
multipoint nonparametric LOD (LOD*) scores because
nonparametric linkage (NPL) analysis is robust to model
assumptions of inheritance.30 In order to avoid the poten-
tial drawback of missing important linkage regions, we
classiﬁed regions with LOD scores greater than 1.5 as
interesting, though this may increase the risk of following
up false-positive results.17
Many interesting two-point MLOD scores (MLOD R 2)
were detected (data not shown). Following our approach
in the original genomic screen,17 to choose themost prom-
ising intervals for follow-up, we also examined the data
with multipoint linkage analysis methods and selected
regions of interest that generated LOD scores >1.5 on, 2009
Figure 1. Multipoint Parametric and Nonparametric LOD Scores for the Overall Data Set
Multipoint maximized LOD scores for the dominant model (black) and the recessive model (blue) allowing for heterogeneity and nonpara-
metric LOD* scores (red) are plotted as a function of marker location (scaled to the size of the chromosome). Chromosome number is at
the top of each plot. Overall data set size, 278 families.both the two-point andmultipoint analyses. A plot of mul-
tipoint MLOD scores for the genome-wide linkage screen is
shown in Figure 1. Multipoint dominant MLOD (black),
recessive MLOD (blue), and LOD* scores (red) are plotted.
The parametric MLOD scores are generally higher than
LOD* scores. The highest multipoint MLOD scores were
obtained under a dominant model of inheritance in an
11 cM interval on chromosome 3q25, at RS755763
(MLOD¼ 2.0; 1 LOD-down support interval: 153 to 164 cM)
and in a 9 cM interval on chromosome 18q11 at RS948384
(MLOD ¼ 1.8; 1 LOD-down support interval: 40 to 49 cM).
The proportions of linked families for these regions were
0.19 (3q25) and 0.18 (18q11). These were also the only
two regions with both two-point and multipoint LOD
scores >1.5. Table 2 shows the SNPs that have two-point
MLOD scores greater than 1.5 within the two candidate
regions. RS902432 on chromosome 3 gives two-point
MLOD scores of 1.57 and 2.54 for the dominant and reces-
sive models, respectively. RS1972602 on chromosome 18
gives two-point MLOD score of 1.52 for the recessive
model. The corresponding multipoint MLOD scores at
RS902432 and RS1972602 are 1.9 and 1.7, respectively,
under the dominant model.The AmThe families in the ﬁnal data set comprised those
included in the original genomic screen (N ¼ 158) and
families recruited since that screen was completed (N ¼
120), and the current screen did not detect linkage overall
in regions previously implicated (on chromosomes 5, 8,
9, 17, and X) in 2001, so we suspected that clinical and
locus heterogeneity might exist. Therefore, we stratiﬁed
the data set into families included in the original genome
screen and new families added to the current screen. In
the subset of 158 families included in the original screen,
the linkage peaks were in general agreement with our
previous genomic screen report (data not shown).
However, in the 120 families not previously screened, the
Table 2. List of Markers with Two-Point LOD Scores > 1.5
within the Candidate Regions on Chromosomes 3 and 18 for
the Overall Data Set
SNP Location cM
Two-Point MLOD Multipoint MLOD
Dominant Recessive LOD* Dominant
rs902432 3q25 155 1.6 2.5 1.5 1.9
rs1972602 18q11 46 1.0 1.5 1.5 1.7erican Journal of Human Genetics 84, 499–504, April 10, 2009 501
Figure 2. Multipoint Parametric and
Nonparametric LOD Scores for the Newly
Screened Family Set for Chromosomes 3
and 18
Multipoint maximized LOD scores for the
dominant model (black) and the recessive
model (blue) allowing for heterogeneity
and nonparametric LOD* scores (red) are
plotted as a function of marker location
(scaled to the size of the chromosome).
Chromosome number is at the top of each
plot. Newly screened family set size, 120
families.parametric linkage peaks under the dominant model on
chromosome 3 and 18weremuch stronger than the overall
data set (Figure 2). Signiﬁcant evidence for linkage to a 5 cM
interval on chromosome 18 was obtained, with an MLOD
of 4.1 at RS948384 (1 LOD-unit down support interval of
42 to 47 cM and proportion of linked families ¼ 0.39).
On chromosome 3, an MLOD of 2.5 was obtained in an
11 cM interval centered on RS755763 (1 LOD-unit down
support interval from153 to164cMandproportionof linked
families of 0.29). There was little evidence for linkage to
these regions overall in the original 158 families (MLOD ¼
0 in both regions). Generally, one expects linkage to grow
stronger with additional families if the result is true;
however, locus heterogeneity between the subsets might
explain the unexpectedly stronger results in the newly
screened families. A natural question is whether the
strengthening of the linkage peaks on chromosomes 3
and 18 in the newly screened family data set is due to
chance (i.e., a same size random sample canproduce similar
linkage peaks). We randomly selected 120 families (the
number of newly screened families) without replacement
from the overall data set and reran the linkage analysis.
We replicated the procedure 100 times. Only one of the
random selection of families gave linkage peaks as high as
or higher than that observed in the newly screened family
data set (p ¼ 0.01). We conclude from this simulation that
the improvement in the linkage analysis result by stratiﬁca-
tion into original and newly screened subsets was not due
to chance, but rather an indicator of locus heterogeneity
among the families. There is no difference in the mean
number of individuals with PD sampled and the mean
age at onset between the original families and the newly
screened families, and all families were of European, non-
Hispanic ancestry. The ascertainment and diagnostic
criteria were also the same in the two sets of families.
Although there is a difference in the proportion of families
contributed by each ascertainment site to the two subsets
and a greater percentage of families with affected relative
pairs in the newly screened families (Table 1), there is no
difference in evidence for linkage when stratifying families
by site or type of relative pair (affected sibpair versus
affected relative pair).
These linkage regions (and their 1-LOD unit down
support intervals) have not, to our knowledge, been previ-502 The American Journal of Human Genetics 84, 499–504, April 1ously reported by other genome-wide linkage screens of
PD. Neither have they been implicated as associated with
PD in two published genome-wide association screens
(GWAS) for PD.24,26 Although the publicly available
summary results for both data sets available in dbGaP
show there is modest evidence (smallest p ¼ 0.003) for
association with individual SNPs in these two regions,
the results do not implicate a single, common area of the
interval and do not withstand correction for multiple
comparisons. According to NCBI, there are 90 and 76
annotated genes in the chromosome 3 and 18 candidate
regions, respectively. None of these genes has previously
been associated with PD. However, a recently published
study of a large Amish pedigree with parkinsonism and
progressive supranuclear palsy found signiﬁcant evidence
for linkage to a microsatellite marker (D3S1764, 153cM,
LOD ¼ 3.6) near the peak of our chromosome 3 region.27
These results suggest that a gene inﬂuencing development
of a broader parkinsonism phenotype might exist in this
region. Therefore, an interval-wide, tag-SNP-based associa-
tion screen is warranted to identify the genes underlying
the evidence for linkage.
By using a dense (intermarker spacing < 1 cM) genome-
wide linkage SNP panel, we identiﬁed two autosomal
regions linked to PD. Linkage evidence to these two regions
improved when stratifying the sample into previously
screened and newly screened family subsets, indicating
that locus heterogeneity is a prominent feature of this
complex disease and that this heterogeneity must be care-
fully consideredwhen selecting samples for gene identiﬁca-
tion efforts. Identiﬁcation of chromosomal regions linked
to PD is a step toward identifying the genes that, together
and when interacting with the environment, inﬂuence
development of this complex disorder. Fine mapping of
the linkage region through traditional position cloning
and candidate gene evaluation or high-density association
mapping (such as can be achieved with GWAS genotyping
arrays) will also be required to identify the particular vari-
ants responsible for inﬂuencing risk of PD in these regions.
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Note Added in Proof
In a recently published genome-wide association study of 857 PD
cases and 867 controls (Pankratz, N., Wilk, J.B., Latourelle, J.C.,
DeStefano, A.L., Halter, C., Pugh, E.W., Doheny, K.F., Gusella,
J.F., Nichols, W.C., Foroud, T., et al. (2009). Genomewide asso-
ciation study for susceptibility genes contributing to familial
Parkinson disease. Hum. Genet. 124, 593–605), one intronic SNP
(rs12638253), at the distal edge of our chromosome 3 linkage
region, was among the 30 providing the strongest evidence for
association with PD (p < 0.0001) under an additive model. These
results support the existence of a PD locus in this region on
chromosome 3., 2009
